Research group applications for Angelman alliance funding are due by June 30th
The Angelman Syndrome Alliance (ASA) has issued a call for research grants, offering an opportunity for scientists from all over the world to delve deeper into the enigma of Angelman syndrome. This genetic disorder, caused by mutations in the UBE3A gene, affects the nervous system and results in severe intellectual disability, speech impairment, and frequent seizures.
The grant programme, open to researchers from any country, is aimed at funding basic research on Angelman syndrome. The grants, totalling up to €120,000 (approximately $130,000), will cover research on the genetic and molecular processes of the syndrome, with the aim of uncovering new insights and potential treatments.
To apply, researchers must submit a detailed description of their planned scientific project, including a review of what's already known, exact plans for experiments, and discussions of specific goals and expected significance. Alongside this, applicants are required to include a curriculum vitae and details of a planned budget.
Applicants can apply for these grants on the ASA's website, where they will also find full application instructions and the registration to submit a grant. The deadline for grant applications is at the end of June.
Successful applicants will be notified at the start of 2024, with the grant funding period beginning in April for those selected. Selected applicants must present their results at ASA's biannual conferences and produce detailed reports on their findings for the ASA midway through the project and once the project is over.
The ASA includes more than a dozen organisations in countries across Europe, as well as Israel and Japan. For any queries about the grant application process or doing research in Angelman syndrome, applicants can contact the ASA via their website.
The ASA's grant programme offers a unique opportunity for researchers to contribute to the understanding of Angelman syndrome and potentially pave the way for new treatments. The maximum grant duration is flexible, with a maximum of four years, providing ample time for ground-breaking research.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
